Deep Braining...
TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

Precigen, Inc. Common Stock (PGEN)
Precigen, Inc. Common Stock
XNAS:PGEN
3.87
3.48%

Ask
$3.96 - 2,000.00
Bid
$3.80 - 300.00
Low
$3.72
High
$3.92
Open
$3.77
Prev Close
$3.74
52W High
5.23
52W Low
0.65
Volume
1777771
Avg Vol (3m)
5622878.4
Float
149279407.07
Chart
TendieTensor AI Analysis

Company
Asset Type: Common Stock
SIC Code: 2834
Sector: Health Technology
Industry: Biotechnology
Date Listed: 08/08/2013
Primary Exchange: XNAS

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Phone: 301-556-9900
Address: 20374 Seneca Meadows Parkway
City: Germantown
State: MD
Postal Code: 20876
TendieTensor AI Analyst Recommendation:
Fundamentals
Total Employees:
25
P/E (TTM)
-2.730000
P/B (TTM)
32.367100
EPS
-1.06
Round Lot
100
Composit FIGI
BBG000QL8VH9
Share Class FIGI
BBG001SSB3T5
Share Class Shares Outstanding
297.97M
Weighted Shares Outstanding
352.91M

Technicals
RSI (14)
MACD Line
MACD Signal
SMA 20
SMA 50
EMA 50
Trend
Short Interest
Days to Cover
Higher = harder to cover
Short Interest Δ
Prev: —
Short Volume Ratio (Today)
5D avg:
Squeeze Score (0–100)
Discussion
Login to participate in discussions.
Recent News
Related Stocks

Based on the portfolios of people who own PGEN. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.